Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies. Anti-amyloid antibodies are regarded as a substantial innovation with an important clinical impact. In addition, however, new compounds with other mechanisms of action and/or route of administration are also needed. Approval of new treatments will require changes to existing patient pathways and real-world data needs to be generated. Comprehensive guidance is provided on the potential implementation of anti-amyloid antibody therapies in Europe following possible approval. Emphasis is placed on the necessity of regularly updating recommendations as new evidence emerges in the coming years.

What this study adds

Evidence grade: Low

Individual members of the European Alzheimer's Disease Consortium issued 24 recommendations on how anti-amyloid antibody therapy could be introduced in Europe if approved, including effects on health care systems and diagnostic pathways. They call the antibodies a substantial innovation but also say new compounds with other mechanisms are needed and recommendations must be updated as evidence emerges.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Frederiksen, K. S., Boada, M., Dubois, B., Engelborghs, S., Frisoni, G. B., Georges, J., et al. (2025). Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01766-y

Vancouver

Frederiksen KS, Boada M, Dubois B, Engelborghs S, Frisoni GB, Georges J, et al. Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01766-y. PMID: 40413561.

BibTeX

@article{frederiksen2025-40413561,
  author  = {Frederiksen, Kristian Steen and Boada, Merçé and Dubois, Bruno and Engelborghs, Sebastiaan and Frisoni, Giovanni Battista and Georges, Jean and Hort, Jakub and Jönsson, Linus and others},
  title   = {{Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC}},
  journal = {Alzheimer s Research \& Therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01766-y},
  pmid    = {40413561},
  url     = {https://doi.org/10.1186/s13195-025-01766-y}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Individual members of the European Alzheimer's Disease Consortium issued 24 recommendations on how anti-amyloid antibody therapy could be introduced in Europe if approved, including effects on health care systems and diagnostic pathways. They call the antibodies a substantial innovation but also say new compounds with other mechanisms are needed and recommendations must be updated as evidence emerges.

Study details

How this study scored 40/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 40 of 100.40 of 100 points earned60 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy)
Journal's citation record 1 / 4 Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 5 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Lutz Froelich: h-index 33 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 40 institution(s) in 15 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40413561)
Free to read 2 / 2 Free to read
Total 40 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Related studies in Treatments from nearby years

Also in Treatments

194 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →